Chemoradiotherapy arm + Immunotherapy + Radiotherapy arm
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Oropharyngeal Squamous Cell Carcinoma
Conditions
Oropharyngeal Squamous Cell Carcinoma
Trial Timeline
Mar 15, 2019 → Feb 14, 2023
NCT ID
NCT03623646About Chemoradiotherapy arm + Immunotherapy + Radiotherapy arm
Chemoradiotherapy arm + Immunotherapy + Radiotherapy arm is a phase 2 stage product being developed by AstraZeneca for Oropharyngeal Squamous Cell Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03623646. Target conditions include Oropharyngeal Squamous Cell Carcinoma.
What happened to similar drugs?
0 of 2 similar drugs in Oropharyngeal Squamous Cell Carcinoma were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03623646 | Phase 2 | Completed |
Competing Products
12 competing products in Oropharyngeal Squamous Cell Carcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Micafungin | Astellas Pharma | Phase 1 | 29 |
| Cetuximab + Cisplatin | Eli Lilly | Phase 2 | 27 |
| Durvalumab + Tremelimumab | AstraZeneca | Phase 1/2 | 24 |
| Cisplatin + Durvalumab + Tremelimumab | AstraZeneca | Phase 2 | 39 |
| Cisplatin + Durvalumab | AstraZeneca | Phase 3 | 44 |
| MEDI0457 + Durvalumab | AstraZeneca | Phase 2 | 27 |
| VB10.16 + Pembrolizumab | Merck | Phase 1/2 | 39 |
| Cetuximab | Merck | Phase 2 | 31 |
| 9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) | Merck | Phase 3 | 44 |
| Paclitaxel + Carboplatin + Nivolumab | Bristol Myers Squibb | Phase 2 | 35 |
| Cyclophosphamide + IRX-2 + Nivolumab | Bristol Myers Squibb | Phase 1 | 21 |
| CUE-101 | Cue Biopharma | Phase 2 | 32 |